Related Experiment Video
Updated: Oct 2, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Is implantable cardioverter defibrillator surgery in patients with an implanted left ventricular assist device safe
Maximilian Vondran1,2, Konstantin von Aspern1, Jens Garbade1
1University Department for Cardiac Surgery, Heart Center Leipzig, Leipzig, Germany.
Insights
Uninterrupted oral anticoagulation for patients with left ventricular assist devices (LVAD) undergoing implantable cardioverter-defibrillator (ICD) surgery is safe. This strategy significantly reduces hospital stay without increasing adverse events compared to heparin bridging.
Area of Science:
- Cardiology
- Medical Devices
- Surgical Procedures
Background:
- Implantable cardioverter-defibrillator (ICD) surgery in patients with left ventricular assist devices (LVAD) carries a high bleeding risk due to necessary anticoagulation.
- Current practices often involve heparin bridging, which may increase complications.
Purpose of the Study:
- To evaluate the safety and efficacy of uninterrupted oral anticoagulation versus heparin bridging during ICD surgery in LVAD patients.
- To compare bleeding complications, re-exploratory surgery rates, and hospital length of stay between the two anticoagulation strategies.
Main Methods:
- A retrospective study of 116 LVAD patients undergoing ICD surgery between January 2009 and January 2020.
- Patients were divided into two groups: continued oral anticoagulation with a vitamin K antagonist (VKA group, n=60) and heparin bridging (heparin group, n=56).
- Demographics, perioperative data, complications, and mortality were analyzed.
Main Results:
- The heparin group showed a trend towards more bleeding complications (19.6% vs. 10.0%) and re-exploratory surgeries (14.3% vs. 5.0%), though not statistically significant.
- Patients in the heparin group had a significantly longer postoperative hospital stay (17.8 days vs. 8.3 days, p=0.007).
- No procedure-related deaths, thromboembolic events, or LVAD thrombosis were observed in either group.
Conclusions:
- Uninterrupted oral anticoagulation is a safe strategy for LVAD patients undergoing ICD surgery.
- This approach more than halves the number of hospital days without an increase in adverse events.
- The findings support a shift towards uninterrupted anticoagulation in this high-risk patient population.
Background:
Implantable cardioverter-defibrillator (ICD) surgery in patients with implanted left ventricular assist devices (LVAD) is associated with an increased risk of bleeding complications because of the need to ensure that these patients are adequately anticoagulated. Our study aimed to evaluate the safety of our new strategy of uninterrupted oral anticoagulation compared to heparin-bridging during the surgical interval.
Methods:
Between January 2009 and January 2020, 116 patients with LVAD underwent ICD surgery. Since January 2015, 60 patients were operated under continued sufficient oral anticoagulation with a vitamin k antagonist (VKA group). Fifty-six patients underwent a heparin-bridging regimen (heparin group). Demographics, perioperative data, complications, and mortality were analyzed.
Results:
Bleeding complications attributable to the surgical intervention occurred more often (19.6% vs. 10.0%, p = 0.142) and at a higher rate of re-exploratory surgery (14.3% vs. 5.0%, p = 0.088) in the heparin group without reaching statistical significance. Moreover, the heparin group patients' postoperative total length of stay was 10 days longer (17.8 ± 23.8 days vs. 8.3 ± 9.5 days, p = 0.007). There were no procedure-related deaths, no thromboembolic events, and no LVAD-related thrombosis.
Conclusion:
Our strategy of uninterrupted oral anticoagulation is safe and results in a reduction by more than half the number of days in hospital without an increase in adverse events.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiac Catheterization IV: Nursing Management
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Cardiac Catheterization III: Left Heart Catheterization
Venous Thrombosis III: Interprofessional Care
Aneurysm IV: Nursing Management

